AIM: To describe nation-wide secular trends in statin use. METHODS: Reimbursed prescriptions for lipid lowering drugs between 1995 and 2005 in Finland were retrieved from the nation-wide Prescription Register. The 1 year prevalence and incidence of statin use stratified by gender and age of users were measured for each calendar year. The relative changes (RR) in the incidence and the prevalence were calculated by using the year 1995 as a reference. RESULTS: The 1 year prevalence increased 11-fold (95% confidence interval 11.2, 11.5), i.e. from 7.8 per 1000 inhabitants in 1995 to 88.9 in 2005. The incidence increased five-fold (95% CI 4.9, 5.1) from 355 per 100 000 inhabitants to 1772 during the respective years. The prevalence and incidence were the highest among persons aged 65-74 years. The largest relative increase in incidence was found among those aged >/= 75 years, in both females (RR 14.1, 95% CI 13.0, 15.3) and males (RR 14.0, 95% CI 12.5, 15.7). Since 2002 the prevalence has been higher among females (P < 0.05). CONCLUSIONS: As statin use has increased particularly among the elderly, further studies on the benefits in real life situation are needed in this age group.
AIM: To describe nation-wide secular trends in statin use. METHODS: Reimbursed prescriptions for lipid lowering drugs between 1995 and 2005 in Finland were retrieved from the nation-wide Prescription Register. The 1 year prevalence and incidence of statin use stratified by gender and age of users were measured for each calendar year. The relative changes (RR) in the incidence and the prevalence were calculated by using the year 1995 as a reference. RESULTS: The 1 year prevalence increased 11-fold (95% confidence interval 11.2, 11.5), i.e. from 7.8 per 1000 inhabitants in 1995 to 88.9 in 2005. The incidence increased five-fold (95% CI 4.9, 5.1) from 355 per 100 000 inhabitants to 1772 during the respective years. The prevalence and incidence were the highest among persons aged 65-74 years. The largest relative increase in incidence was found among those aged >/= 75 years, in both females (RR 14.1, 95% CI 13.0, 15.3) and males (RR 14.0, 95% CI 12.5, 15.7). Since 2002 the prevalence has been higher among females (P < 0.05). CONCLUSIONS: As statin use has increased particularly among the elderly, further studies on the benefits in real life situation are needed in this age group.
Authors: S Riahi; K Fonager; E Toft; L Hvilsted-Rasmussen; J Bendsen; S Paaske Johnsen; H T Sørensen Journal: Br J Clin Pharmacol Date: 2001-09 Impact factor: 4.335
Authors: James Shepherd; Gerard J Blauw; Michael B Murphy; Edward L E M Bollen; Brendan M Buckley; Stuart M Cobbe; Ian Ford; Allan Gaw; Michael Hyland; J Wouter Jukema; Adriaan M Kamper; Peter W Macfarlane; A Edo Meinders; John Norrie; Chris J Packard; Ivan J Perry; David J Stott; Brian J Sweeney; Cillian Twomey; Rudi G J Westendorp Journal: Lancet Date: 2002-11-23 Impact factor: 79.321
Authors: Aukje K Mantel-Teeuwisse; Olaf H Klungel; W M Monique Verschuren; Arijan J Porsius; Anthonius de Boer Journal: Br J Clin Pharmacol Date: 2002-04 Impact factor: 4.335
Authors: Jenni E Keskitalo; Kaisa J Kurkinen; Mikko Neuvonen; Janne T Backman; Pertti J Neuvonen; Mikko Niemi Journal: Br J Clin Pharmacol Date: 2009-08 Impact factor: 4.335
Authors: Jukka Pulkkinen; Matti Eskelinen; Vesa Kiviniemi; Tuukka Kotilainen; Markus Pöyhönen; Lasse Kilpeläinen; Pirjo Käkelä; Helena Kastarinen; Hannu Paajanen Journal: BMC Gastroenterol Date: 2014-07-03 Impact factor: 3.067